Xencor, Inc. (NASDAQ:XNCR) Shares Sold by DCF Advisers LLC

DCF Advisers LLC reduced its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 3.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 203,167 shares of the biopharmaceutical company’s stock after selling 6,312 shares during the period. Xencor comprises approximately 2.3% of DCF Advisers LLC’s holdings, making the stock its 14th largest holding. DCF Advisers LLC owned about 0.29% of Xencor worth $4,669,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in XNCR. Point72 Asset Management L.P. raised its position in shares of Xencor by 147.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock valued at $62,748,000 after acquiring an additional 1,858,440 shares in the last quarter. RTW Investments LP acquired a new stake in shares of Xencor during the 3rd quarter valued at approximately $11,563,000. RA Capital Management L.P. acquired a new stake in shares of Xencor during the 3rd quarter valued at approximately $11,563,000. Braidwell LP acquired a new stake in shares of Xencor during the 3rd quarter valued at approximately $9,380,000. Finally, Erste Asset Management GmbH acquired a new stake in shares of Xencor during the 3rd quarter valued at approximately $7,087,000.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. StockNews.com downgraded Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. Finally, Wells Fargo & Company lowered their price objective on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Xencor presently has an average rating of “Moderate Buy” and an average target price of $34.38.

Xencor Trading Up 2.5 %

NASDAQ:XNCR opened at $13.47 on Friday. Xencor, Inc. has a 1 year low of $12.54 and a 1 year high of $27.24. The stock has a market cap of $949.12 million, a price-to-earnings ratio of -4.21 and a beta of 0.75. The business has a fifty day moving average of $16.51 and a 200-day moving average of $20.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $52.79 million during the quarter, compared to analysts’ expectations of $17.14 million. Equities analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.